Plasma Vitamin and Homocysteine Levels and Thrombosis in Patients With Ph-negative MPNs

Plasma Cobalamin, Folate, Pyridoxine and Homocysteine Levels and Thrombosis in Patients With Philadelphia-chromosome-negative Myeloproliferative Neoplasms

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01878916

Enrollment

Unknown

Registered

2013-06-17

Start date

2003-01-31

Completion date

2004-06-30

Last updated

2013-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombosis

Keywords

the incidence of thrombosis,, the effect of Hcy on thrombosis formation,, the relation between Hcy and plasma vitamin levels,, to compare these results with the control group

Brief summary

Hyperhomocysteinemia is a risk for thrombosis. Thrombosis is more frequent in myeloproliferative neoplasms (MPNs) than the normal population. In this study, we investigated the thrombosis incidence, the effects of plasma homocysteine levels on thrombosis, and the correlations between folate, cobalamin, pyridoxine and homocysteine levels in MPNs, and to compare these results with the healthy controls.

Detailed description

Thirty-one new or formerly diagnosed MPN patients who consecutively visitted our outpatient clinic, as well as 40 age and sex matched healthy controls were enrolled in this study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Adult MPN patients and healthy controls who gave a written consent were included in the study.

Design outcomes

Primary

Measure	Time frame
Thrombosis	at least 1 year

Secondary

Measure	Time frame
High Hcy level	1 year

Other

Measure	Time frame
Death	1 year

Countries

Turkey (Türkiye)

Outcome results